Recent clinical studies have shown that SGLT2 inhibitors can also benefit NAFLD patients, including improved lipid accumulation in the liver, ballooning degeneration, fibrosis, and liver injuries [5,6]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.